IQVIA Real-World Data Adjudicated Claims: USA [QuintilesIMS PharMetrics Plus]

Field Names
Records
Coordinating Country
United States
Region

U.S. Census Regions - East, Southeast, Midwest, West (Now available at the state and the 3-digit ZIP code level)

Brief Database Description

QuintilesIMS (QI) RWD Adjudicated Claims: USA [PharMetrics Plus] is a QuintilesIMS-owned dataset which includes fully adjudicated pharmacy, hospital and medical claims at the anonymized patient level, sourced from commercial payers covering over 100 million enrollees from 2007 to present. More importantly, approximately 47 million enrollees are covered with both pharmacy and medical coverage in the most recent 12 months. The data held in PharMetrics Plus covers applications such as patient treatment patterns and treatment flows, adherence and persistence information, costs and resource utilization, burden of illness and pharmacovigilance and safety studies. The enrollee population in the PharMetrics Plus database is generally representative of the less-than-65 years of age, commercially insured population in the US with respect to both age and gender. The database consists primarily of commercial PPO plans and can thus under-represent the patients on Medicaid or Medicare relative to patients on commercial plans (i.e., >65 population). The database includes ~150 Million patients with a medical benefit, and a subset of 95 Million patients with both medical and pharmacy benefits. Data include: - Diagnoses (ICD-9-CM); - Procedures (CPT, HCPCS, ICD-9-CM); - Diagnostic & lab tests ordered (no lab values).

Also included are data on:
- Enrollment
- Adverse events
- Hospitalizations
- Office visits
- ER visits
- Home care
- Cost & Data of treatment
- On/off formulary status
- Co pays / Deductibles
- Complete medical and pharmacy costs.

This database can be useful for the following:
- Patient treatment patterns (flows)
- Market opportunity assessment
- Medication adherence
- Patient & provider segmentation
- Blocked product market analysis
- Orphan drugs & conditions
- Insight into blocked products
- Burden of illness
- Pharmacovigilance & safety
- Cost of resource utilization
- Comparative effectiveness
- Epidemiological prevalence & incidence.

Through a unique and proprietary algorithm, data from QuintilesIMS RWD Adjudicated Claims: USA can be linked to other QuintilesIMS patient-level databases (e.g., Electronic Medical Records, Hospital Charge Detail Master, etc.) or clients' patient-level databases (e.g., from registries or clinical trials).

Database Type
Longitudinal Population Database
- Drug and Diagnosis Data
- - Medical and Pharmacy Insurance Claims
- - - Outpatient and inpatient
Database Source
Medical Insurance Claims

[Fully adjudicated health plan medical and pharmacy claims.
NOTE: Due to the ability of QuintilesIMS RWD Adjudicated Claims: USA to link to other patient level databases, data from disparate sources can be linked upon request (e.g., from Electronic Medical Record, Registries, Laboratory data) to provide additional clinical detail]

Frequency of Data Collection
Ongoing
Frequency of Data Update
Ongoing
Years Covered
2007 - Present
Population Type
Insured

(Commercially insured US population, with subset of commercially insured Medicaid and Medicare patients.
NOTE: Due to the broad reach of the data, records in the QuintilesIMS RWD Adjudicated Claims: USA database are representative of the national, commercially insured population in terms of age and gender for individuals aged 65 years and under.)

Patient Type
Inpatient and Outpatient

Emergency Room
Other
(Inpatient and Outpatient Hospital, Pharmacy, Office, ER/ED, Home Health, Pathology, Radiology, Clinic)

Date of Last Update
Ongoing

(QuintilesIMS RWD Adjudicated Claims: USA is updated on an ongoing basis;
This profile was last updated for the B.R.I.D.G.E. TO DATA site on May 8, 2017.)

Field Names
Records
Database Population Size
> 100 Million

NOTE: More than 150 Million enrollees with >100 Million who have both medical and pharmacy coverage

Active Population Size
> 100 Million

NOTE: More than 150 Million enrollees with >100 Million who have both medical and pharmacy coverage

Annual Change in Population
12%-15%
Sample Weights - Extrapolation Factors
No
Final Population Size
N/A

(Not applicable as data collection is ongoing)

Field Names
Records
Age of Patients at Data Collection
Yes

(YOB)
YOB on enrollment records and age at the time of the medical encounter is recorded on the medical claim record

Approximate Percentage of Participants <18 years and those >65 years

<18 = 30-35%
>65 = 10-12%

Gender Data
Yes
Percentage of Males/Females

Males = 50%
Females = 50%

Ethnicity / Race Data
No

However, this is a variable present in another QuintilesIMS offering that can be linked to the QuintilesIMS RWD Adjudicated Claims: USA data (QuintilesIMS Consumer Data)

Geographic Location

U.S. Census Region (East, Southeast, Midwest, West) and state

NOTE: 3-digit zip is optional

Date of Birth Recorded
Yes

(Year of Birth)

Death Recorded
No

For hospital stays, discharge status may indicate death. This is a variable present in another IMS offering that can be linked to the QuintilesIMS RWD Adjudicated Claims: USA data (QuintilesIMS Consumer Data).

Availability of death certificate / autopsy information
No
Other Demographic Data
No

However, this is a variable present in another QuintilesIMS offering that can be linked to the QuintilesIMS RWD Adjudicated Claims: USA data (QuintilesIMS Consumer Data)

Field Names
Records
Physician ID
Yes

NOTE: Physician ID is an optional variable in the database

Physician Specialty
Yes
Pharmacy ID
Yes

NOTE: Pharmacy ID is an optional variable in the database

Field Names
Records
Diagnosis Data
Yes
Diagnoses Coded
ICD-9-CM

ICD-10-CM

Diagnoses: Date Parameters
2006 - Present
Diagnoses: Maximum Number of Codes Allowed
12

(Up to 12 diagnoses per record are included in the database; however there could be up to 13 diagnoses per record for inpatient as this includes their admitting diagnosis or reason for admission.)

Physical Examination Findings
Yes

However, only if evidenced by clinical coding present on claim

Birth Defect Data
Yes

(If evidenced by clinical coding present on claim)

Cancer Data
Yes

(If evidenced by clinical coding present on claim. QuintilesIMS RWD Adjudicated Claims: USA data can be linked to QuintilesIMS' Oncology EMR data.)

Infectious Disease Data
Yes

(If evidenced by clinical coding present on claim)

Environmental Exposures
Yes

(If evidenced by clinical coding present on claim)

Behavioral Data Elements
Yes

(If coded on claim, e.g., smoking or alcohol overuse)

Field Names
Records
Procedure Data
Yes
Procedures Coded
CPT
HCPCS
ICD-10
ICD-9
Other

[CPT-4 procedure codes
HCPCS
ICD-9-PCS and ICD-10-PCS (Inpatient Procedure codes)
Revenue Codes]

Number of Procedures Coded
Unlimited

[One procedure per record (claim line) for CPT-4, HCPCS and Revenue Code. Up to 12 codes per record for ICD-9 procedure codes.]

Procedure Date Parameters
2006 - Present
Laboratory Information
No

However, this is a variable present in another QuintilesIMS offering that can be linked to the QuintilesIMS RWD Adjudicated Claims: USA data (IMS Laboratory Data or QuintilesIMS Ambulatory EMR Data)

Field Names
Records
Drug Data
Yes: Prescription only

OTC and written prescriptions are present in another QuintilesIMS offering that can be linked to the PharMetrics Plus data

Drug Date Parameters
2007 - Present
Drug Regimen & Route
Yes

Via, quantity, and days supply as appropriate.

Drug Manufacturer
No

However, this may be determined by NDC codes

Drug Dosage
Yes

NDC gives dose form, but not number prescribed or Sig. However, this information is a variable present in another QuintilesIMS offering that can be linked to the QuintilesIMS RWD Adjudicated Claims: USA data (QuintilesIMS Ambulatory EMR Data:USA).

Drug Days Supply
Yes
Drug Coding System: Maximum Number
1

(1 drug per record; no limit to records per day)

Drug Coding System: Primary
NDC

HCPCS
(Mapping tables to AHFS, USC available)

Drug Coding System: Other
N/A
Drug Generic Name
Yes

Generic name is provided via look-up table

Drug Additional Information
Yes

Formulary status, Dispense As Written (DAW) are available at the claim line level

Field Names
Records
Cost Data
Yes
Cost Denomination
US Dollars
Type of Cost Data
Yes

(Allowed and actual paid amounts)

Description of Surrogate Link
N/A

(Not applicable)

Field Names
Records
Data Validation Against Original Source
No
Access to Medical Records
No
Linkage to Other Databases
Yes

Through a unique and proprietary algorithm, data from QuintilesIMS RWD Adjudicated Claims: USA can be linked to other QuintilesIMS patient-level databases (e.g., Electronic Medical Records, Hospital Charge Detail Master, etc.) or clients' patient-level databases (e.g., from registries or clinical trials).

Brief Description of Linkage Capabilities

QuintilesIMS utilizes a patented HIPAA compliant algorithm for linking patients across data sources. Using a deterministic (not probabilistic) matching process, QuintilesIMS is able to link patients using a common ID across disparate sources of data.

Field Names
Records
Database Contact Data

Carmela Semonelli
Engagement Manager
Real World Evidence Solutions
QuintilesIMS 35 Corporate Drive, Suite 450
Burlington, MA 01803 USA
Office: +1 (781) 685-3033
Email: Carmela.Semonelli@IQVIA.com

Alternate Contact

Mira Lichtenstein
Senior Principal
Real-World Evidence Solutions
IQVIA
One IMS Drive
Plymouth Meeting, PA 19462
USA
Office: +1 (484) 567-6460
Email: Mira.Lichtenstein@IQVIA.com

Source of Database Funding
Private

(Owned by QuintilesIMS)

Sponsoring Government Agency
N/A

(Not applicable)

Sponsoring Pharmaceutical Manufacturer

N/A

(Not applicable)

Database Usage Restrictions
Private Access

(License specific)

Charge for Database Usage
Yes

Fee is involved for using the dataset; please contact the database manager for more details

Data Media Format
Other

(Standard format is Pipe Delimited. A SAS executable template can be provided upon request. Data can be delivered via FTP to a client's AMAZON S3 account or via a QI supplied, encrypted hard-drive.)

Number of Publications Using Database
>10
References of Studies Using/Describing Database

1. Ma Q, Chen YJ, Hines DM, Munakata J, Batty N, Barber BL, Zhao Z. Patterns of use of systemic therapies among patients with metastatic melanoma: a retrospective claims database analysis in the United States. J Dermatolog Treat. 2017 Jan 19:1-8. 2. Jones C, Fike DA, Peres P. Investigation of the Quasi-Simultaneous Arrival (QSA) Effect on a CAMECA IMS 7f-GEO. Rapid Commun Mass Spectrum. 2017 Jan 17.[Epub ahead of print] 3. Simeone JC, Luthra R, Kaila S, Pan X, Bhagnani TD, Liu J, Wilcox TK. Initiation of triple therapy maintenance treatment among patients with COPD in the US. Int J Chron Obstruct Pulmon Dis. 2016 Dec 22; 12:73-83. 4. Marrett E, Kwong WJ, Frech F, Qian C. Health Care Utilization and Costs Associated with Nausea and Vomiting in Patients Receiving Oral Immediate-Release Opioids for Outpatient Acute Pain Management. Pain Ther. 2016 Dec; 5(2):215-226. 5. Ramos M, Haughney J, Henry N, Lindner L, Lamotte M. Cost versus utility of aclidinium bromide 400 µg plus formoterol fumarate dihydrate 12 µg compared to aclidinium bromide 400 µg alone in the management of moderate-to-severe COPD. Clinicoecon Outcomes Res. 2016 Sep 12; 8:445-56. 6. Cui M, Tu CC, Chen EZ, Wang XL, Tan SC, Chen C. A Cost-Effectiveness Analysis of Clopidogrel for Patients with Non-ST-Segment Elevation Acute Coronary Syndrome in China. Adv Ther. 2016 Sep; 33(9):1600-11. 7. Saito H, Kashiyama H, Murohashi T, Sasaki K, Misawa R, Ohwada S. Case of Six-Year Disease-Free Survival with Undifferentiated Carcinoma of the Pancreas. Case Rep Gastroenterol. 2016 Aug 31; 10(2):472-478. 8. Dasa V, DeKoven M, Sun K, Scott A, Lim S. Clinical and cost outcomes from different hyaluronic acid treatments in patients with knee osteoarthritis: evidence from a US health plan claims database. Drugs Context. 2016 Jun 23;5:212-296 . 9. Morlock R, Chevalier P, Horne L, Nuevo J, Storgard C, Aiyer L, Hines DM, Ansolabehere X, Nyberg F. Disease Control, Health Resource Use, Healthcare Costs, and Predictors in Gout Patients in the United States, the United Kingdom, Germany, and France: A Retrospective Analysis. Rheumatol Ther. 2016 Jun;3(1):53-75. 10. Risson V, Saini D, Bonzani I, Huisman A, Olson M. Patterns of Treatment Switching in Multiple Sclerosis Therapies in US Patients Active on Social Media: Application of Social Media Content Analysis to Health Outcomes Research. J Med Internet Res. 2016 Mar 17; 18(3):e62.

Database Contact
Database Contact Data

Carmela Semonelli
Engagement Manager
Real World Evidence Solutions
QuintilesIMS 35 Corporate Drive, Suite 450
Burlington, MA 01803 USA
Office: +1 (781) 685-3033
Email: Carmela.Semonelli@IQVIA.com

Alternate Contact

Mira Lichtenstein
Senior Principal
Real-World Evidence Solutions
IQVIA
One IMS Drive
Plymouth Meeting, PA 19462
USA
Office: +1 (484) 567-6460
Email: Mira.Lichtenstein@IQVIA.com

References of Studies Using/Describing Database

1. Ma Q, Chen YJ, Hines DM, Munakata J, Batty N, Barber BL, Zhao Z. Patterns of use of systemic therapies among patients with metastatic melanoma: a retrospective claims database analysis in the United States. J Dermatolog Treat. 2017 Jan 19:1-8. 2. Jones C, Fike DA, Peres P. Investigation of the Quasi-Simultaneous Arrival (QSA) Effect on a CAMECA IMS 7f-GEO. Rapid Commun Mass Spectrum. 2017 Jan 17.[Epub ahead of print] 3. Simeone JC, Luthra R, Kaila S, Pan X, Bhagnani TD, Liu J, Wilcox TK. Initiation of triple therapy maintenance treatment among patients with COPD in the US. Int J Chron Obstruct Pulmon Dis. 2016 Dec 22; 12:73-83. 4. Marrett E, Kwong WJ, Frech F, Qian C. Health Care Utilization and Costs Associated with Nausea and Vomiting in Patients Receiving Oral Immediate-Release Opioids for Outpatient Acute Pain Management. Pain Ther. 2016 Dec; 5(2):215-226. 5. Ramos M, Haughney J, Henry N, Lindner L, Lamotte M. Cost versus utility of aclidinium bromide 400 µg plus formoterol fumarate dihydrate 12 µg compared to aclidinium bromide 400 µg alone in the management of moderate-to-severe COPD. Clinicoecon Outcomes Res. 2016 Sep 12; 8:445-56. 6. Cui M, Tu CC, Chen EZ, Wang XL, Tan SC, Chen C. A Cost-Effectiveness Analysis of Clopidogrel for Patients with Non-ST-Segment Elevation Acute Coronary Syndrome in China. Adv Ther. 2016 Sep; 33(9):1600-11. 7. Saito H, Kashiyama H, Murohashi T, Sasaki K, Misawa R, Ohwada S. Case of Six-Year Disease-Free Survival with Undifferentiated Carcinoma of the Pancreas. Case Rep Gastroenterol. 2016 Aug 31; 10(2):472-478. 8. Dasa V, DeKoven M, Sun K, Scott A, Lim S. Clinical and cost outcomes from different hyaluronic acid treatments in patients with knee osteoarthritis: evidence from a US health plan claims database. Drugs Context. 2016 Jun 23;5:212-296 . 9. Morlock R, Chevalier P, Horne L, Nuevo J, Storgard C, Aiyer L, Hines DM, Ansolabehere X, Nyberg F. Disease Control, Health Resource Use, Healthcare Costs, and Predictors in Gout Patients in the United States, the United Kingdom, Germany, and France: A Retrospective Analysis. Rheumatol Ther. 2016 Jun;3(1):53-75. 10. Risson V, Saini D, Bonzani I, Huisman A, Olson M. Patterns of Treatment Switching in Multiple Sclerosis Therapies in US Patients Active on Social Media: Application of Social Media Content Analysis to Health Outcomes Research. J Med Internet Res. 2016 Mar 17; 18(3):e62.